Antibody-drug conjugates are shifting from promise to proof. For cancers like osteosarcoma and small-cell lung cancer, where progress has been scarce, new breakthrough designations signal real momentum. As Precision CMO Harpreet Singh, MD notes, the ability to combine precision targeting with immuno-oncology may redefine what’s possible for patients who have long had limited options.
Antibody-drug conjugates (ADCs) are emerging as one of the most exciting modalities in oncology. By pairing targeted antibodies with potent payloads, they have the potential to bring precision and efficacy to cancers that have been historically resistant to treatment. GSK’s SVP & Global Head of Precision Medicine, R&D, Anne-Marie Martin, PhD, recently shared in an interview, “Clearly, antibody-drug conjugates (ADCs) are very promising. If they are as successful as the field hopes, they will have the potential to impact a broad range of cancer types and patient populations. Combining them with conventional IO therapies will be part of future IO treatment.” GSK’s B7-H3–targeted ADC has received multiple regulatory designations: - FDA Breakthrough Therapy Designation for adults with relapsed or refractory osteosarcoma who have progressed after at least 2 prior lines of therapy (January) - FDA Breakthrough Therapy Designation for relapsed/refractory extensive-stage small-cell lung cancer (December 2024) - EMA PRIME designation (2024) Osteosarcoma and small-cell lung cancer have long lacked new treatment options, making these designations a significant step toward innovation for patients and families who urgently need it. Precision For Medicine Precision Medicine Group #ADC #BreakthroughDesignation #Osteosarcoma #SCLC